Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Conditions

Recurrence 11Carcinoma, Non-Small-Cell Lung 11Neoplasms 8Prostatic Neoplasms 7Multiple Myeloma 6Breast Neoplasms 6Leukemia, Myeloid, Acute 4Small Cell Lung Carcinoma 3Pancreatic Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Lung Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Lambert-Eaton Myasthenic Syndrome 3HER2-positive Breast Cancer 3Glioma 3Carcinoma, Medullary 3Thyroid Neoplasms 2Stomach Neoplasms 2Pheochromocytoma 2Paraganglioma 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Neoplasm Metastasis 2Myasthenic Syndromes, Congenital 2Lymphoma 2Liver Neoplasms 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia 2Head and Neck Neoplasms 2

Interventions

erdafitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Approved for marketing × Advanced Cancers and FGFR Genetic Alterations × Clear all
NCT03825484 2025-06-13

Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment Options

Janssen Scientific Affairs, LLC

Approved for marketing

Advanced Cancers and FGFR Genetic Alterations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡